Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
Primary Objective: - To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin. Secondary Objectives: * To compare the overall survival (OS) between the 2 treatment arms * To compare the objective response rate (RR) between the 2 treatment arms
Epistemonikos ID: 0f153d586bc4e4892a7d82721948b1f7c1e5d6b5
First added on: Oct 05, 2021